<DOC>
	<DOCNO>NCT00108251</DOCNO>
	<brief_summary>The primary purpose study determine whether eplerenone beneficial effect improve exercise ability patient diastolic heart failure .</brief_summary>
	<brief_title>Aldosterone Antagonism Diastolic Heart Failure</brief_title>
	<detailed_description>The objective study : 1 ) To evaluate effect eplerenone , aldosterone antagonist , intermediate functional outcome patient DHF ( diastolic heart failure ) ; 2 ) To evaluate effect eplerenone , aldosterone antagonist , echocardiographic measure diastolic dysfunction patient DHF . The study double-blind , placebo-controlled study evaluate effect eplerenone compare placebo patient DHF . A total 48 patient DHF randomize 1:1 ratio 1 ) Placebo ( n=24 ) 2 ) Eplerenone ( n=24 ) dose 25 mg day first 2 week follow uptitration 50 mg day 22 week . The primary outcome improvement functional capacity , measure distance cover 6-minute walk test . Secondary Outcomes include : Change echocardiographic measure diastolic dysfunction , change level B-type natriuretic peptide ( BNP ) change quality life .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Diastolic</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<criteria>1 . All patient must DHF define 3 follow criterion : ) Presence clinical heart failure great equal 2 month screen visit . At time enrollment NYHA functional class II III heart failure symptom dyspnea , fatigue exertion , paroxysmal nocturnal dyspnea , orthopnea . ii ) Left ventricular ejection fraction great equal 50 % ( echo , radionuclide angiography contrast angiography ) within 2 month screen iii ) BNP ( brain natriuretic peptide ) great equal 62 pg/ml within 2 month screen 2 . Patients euvolemic clinical examination . If patient euvolemic , attempt make achieve euvolemic state change diuretic dos prior enrollment study 3 . Systolic blood pressure less equal 150 mmHg diastolic blood pressure less equal 95 mmHg 4 week prior time enrollment 4 . Able walk least 50 time enrollment 5 . All patient require ACE inhibitor angiotensin receptor blocker least 4 week prior enrollment 1 . Patients require eplerenone spironolactone treatment comorbid illness , e.g . ascites due cirrhosis . Also , patient severe hepatic impairment include . 2 . Contraindication eplerenone therapy creatinine &gt; 2.5 mg/dl serum potassium &gt; 5.0 mEq/L creatinine clearance &lt; 30 ml/min/1.73 m2 intolerance eplerenone spironolactone past 3 . Significant valvular heart disease , pericardial disease severe chronic lung disease cor pulmonale , cause symptom sign CHF 4 . Patients technically inadequate echocardiographic window patient severe mitral annular calcification 5 . Unstable angina MI within 4 week prior enrollment 6 . Patient severe peripheral vascular disease claudication physical condition limit distance walk 7 . Pregnant lactating female 8 . History alcohol substance abuse history repeat noncompliance medication 9 . History cancer within 3 year ( resect cutaneous basal squamous cell carcinoma ) 10 . Participation drug trial within 30 day prior enrollment 11 . Inability provide inform consent 12 . On drug strong inhibitor CYP3A4 ketoconazole , itraconazole , nefazodone , trolandeomycin , clarithromycin , ritonavir , nelfinavir etc .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>control clinical trial</keyword>
	<keyword>Diastole</keyword>
	<keyword>Echocardiography</keyword>
	<keyword>exercise tolerance</keyword>
	<keyword>Heart Failure , Congestive</keyword>
	<keyword>Receptors , Aldosterone</keyword>
</DOC>